GlassScriptPhysician profile
Jennifer Poterbin
NPI 1093192619
$12,083.32
in general payments reported to CMS, 2019-2025
33 companies · $3,523 in 2025
The $3,523 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $2,095 · 2023: $2,529 · 2024: $2,868 · 2025: $3,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,804 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,803.93 |
| Education | $115.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,772.47 | 2021-2025 | |
| Janssen Biotech, INC. | $1,398.30 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,268.75 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,158.33 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $1,056.94 | 2021-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $642.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $572.22 | 2022-2025 | |
| Ardelyx, INC. | $437.92 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $250.16 | 2022-2024 | Interstim, Gi Genius |
| Qol Medical, LLC | $232.48 | 2021-2025 | Sucraid |
| Celgene Corporation | $221.97 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $218.96 | 2021-2025 | |
| Lilly USA, LLC | $218.17 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $184.53 | 2021-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $149.46 | 2023-2025 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $148.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $144.85 | 2021-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $123.24 | 2021-2024 | Rebyota, Clenpiq |
| Fresenius Kabi USA, LLC | $108.83 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $105.77 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.95 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $102.06 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $91.29 | 2021-2023 | |
| Blueprint Medicines Corporation | $73.35 | 2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $68.93 | 2025 | Zenpep |
| Organon LLC | $61.36 | 2023 | Renflexis, Hadlima |
| Alnylam Pharmaceuticals INC. | $36.31 | 2022 | |
| Horizon Therapeutics Plc | $33.48 | 2021-2022 | |
| Alfasigma USA, INC. | $28.91 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $24.66 | 2023 | Terlivaz |
| Celltrion USA INC. | $15.64 | 2024 | Zymfentra |
| Exact Sciences Corporation | $15.25 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Poterbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.